Study of DISC-0974-201 in Participants With IBD and Anemia
← catalyst calendarNCT07368972 · readout ≤ 73 d
Sponsored by Disc Medicine, Inc (industry) · IRON — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
21estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-20 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Inflammatory Bowel Disease (IBD)
- Anemia
- Inflammatory Bowel Disease (IBD); Anemia
Interventions
- Drug: DISC-0974
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMaximal change from baseline in Hgb through Day 85
measured up to 85 days
Permalink · IRON's whole pipeline · Catalyst calendar · Every registered study · What changed